Semaglutide is a GLP-1 receptor agonist, and you should think of it as a metabolic tool, not a quick fix for looks
Ozempic slows gastric emptying, which can affect the absorption of oral medications, potentially delaying their effects
Clear insurance policies and wider access could help more people stay on semaglutide and get the full benefits of the treatment
This is exactly what you would expect from a drug whose cardiac effects are driven by receptor activation, more drug means more receptor binding means more cAMP means faster heart rate
Wegovy is a glucagon-like peptide-1 receptor agonist (also called a GLP-1 medication) that has been approved by the Food and Drug Administration (FDA) for the following indications: to help with weight loss and long-term weight management in certain adults and children who are overweight or have obesity to reduce the risk of major adverse cardiovascular (CV) events (heart attack, stroke, or CV death) in adults with established cardiovascular disease who are overweight or have obesity to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis Wegovy is typically prescribed as part of a treatment plan that includes a healthy, reduced-calorie diet and regular exercise
When your body loses fluids and electrolytes, it can leave you feeling drained or physically exhausted
